Volume 129, Issue 17

Cover Figure: Single-cell approach to define therapeutic response to kinase treatment in CML. See the article
by Warfvinge et al.

WASHINGTON, April 27, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation
In this plenary paper, Yoshizato et al offer a detailed genomic analysis of a substantial cohort of 797 patients with myelodysplastic syndrome and secondary acute myeloid leukemia (AML) who received unrelated stem cell transplants, and identify unique predictors of outcome.

Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project
Bhatt and colleagues present preclinical data on a novel molecule fusing anti-CD20 to interleukin-21, demonstrating increased efficacy against lymphoma cells in comparison with either agent alone.

How I manage the toxicities of myeloma drugs
In this How I Treat article, Delforge and Ludwig cover the therapeutic management of more and less common treatment-related toxicities in multiple myeloma in relation to distinct patient vignettes derived from clinical practice.

Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy
Cox et al report on a cohort of more than 150 adults with type 1 (non-neuronopathic) Gaucher disease who remained clinically stable after switching from recombinant glucocerebrosidase replacement therapy to eliglustat tartrate, an oral inhibitor of glucocerebroside synthase (a substrate reduction therapy).

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
Why are some patients with chronic myeloid leukemia (CML) resistant to tyrosine kinase therapy? Warfvinge and colleagues use single-cell approaches to characterize the shifting subpopulations of CML stem cells associated with response and resistance.

PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase
Yok-Lam Kwong et al provide evidence that immune checkpoint inhibitors are remarkably effective in the treatment of relapsing NK/T-cell lymphoma.

Slowed decay of mRNAs enhances platelet specific translation
Mills and colleagues examine ribosome-bound mRNAs in resting and activated platelets, and describe a role for the ribosome rescue factor Pelota in regulating mRNA decay in platelets.

Optimized depletion of chimeric antigen receptor T Cells in murine xenograft models of human acute myeloid leukemia
This study presents a method to debulk AML with CD123-redirected chimeric antigen receptor (CAR) T cells, and compares the efficacy of 3 distinct approaches to eliminating the CD123-redirected CAR T cells to limit their persistence.

Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions
This work identifies pentraxin-2 as a binding protein of factor X that is responsible for regulating and maintaining factor X levels in circulation.

Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth
Bujisic and colleagues discover that the IRE1-XBP1s arm of the unfolded protein response, which is essential for cellular homeostasis, is specifically repressed in germinal center B-cell–like diffuse large B-cell lymphoma (GCB DLBCL) by the histone methyltransferase EZH2. Also, they find that recovery of XBP1 (X-box binding protein 1) expression inhibits lymphoma growth.


This week's complete table of contents

Why Submit to Blood?



Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.